Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)